Goldman Sachs Lists Two Stocks as Strong Buy: Unlocking Potential Upside

Despite recent market conservatism, Goldman Sachs analysts have spotlighted two U.S. stocks with substantial upside potential, labelling them as strong buys. But which companies have captured Goldman\'s attention, and why are they so bullish?

Using the TipRanks database, we’ve tracked down two names that currently make the grade not only in the Goldman analysts’ books, but also receive Strong Buy ratings. Goldman’s stock analysts echo Kostin’s outlook and predict a surge of up to 165% for two small-cap stocks.

We ran two of their recent recommendations through the TipRanks database and it looks like the Street is in agreement with the Goldman view here – both are rated as Strong Buy.

One stock specifically mentioned for its potential is Fulcrum Therapeutics [FULC], although Goldman Sachs analyst Richard Law has made two specific stock recommendations, foreseeing substantial upside potential of over 120%. Law’s bullish outlook, combined with the consensus, makes these selections compelling.

According to the TipRanks database, these stocks have attracted overwhelmingly positive sentiment. Goldman Sachs reveals five stocks that it believes have major upside. Overall, there are 3 recent analyst reviews for this recently public stock, and all four are unanimously positive – giving SN its Strong Buy consensus rating. The shares are… promising.

Don\'t miss out on the opportunity to explore these Goldman Sachs-endorsed stocks. Research and consider these potentially high-growth investments today.